First Wave BioPharma Stock (NASDAQ:FWBI), Analyst Ratings, Price Targets, Predictions

The latest price target for First Wave BioPharma (NASDAQ: FWBI) was reported by HC Wainwright & Co. on March 25, 2024. The analyst firm set a price target for $0.00 expecting FWBI to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for First Wave BioPharma (NASDAQ: FWBI) was provided by HC Wainwright & Co., and First Wave BioPharma their neutral rating.

There is no last upgrade for First Wave BioPharma.

The last downgrade for First Wave BioPharma Inc happened on July 14, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for First Wave BioPharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of First Wave BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for First Wave BioPharma was filed on March 25, 2024 so you should expect the next rating to be made available sometime around March 25, 2025.

While ratings are subjective and will change, the latest First Wave BioPharma (FWBI) rating was a with a price target of $0.00 to $0.00. The current price First Wave BioPharma (FWBI) is trading at is $2.77, which is out of the analyst’s predicted range.